Abstract
Pharmacoeconomics is new and modern health science, implemented in developed societies, to play core role in creating health policies. The main aim of pharmacoeconomic analysis is development of science methodology for evaluation of costs and outcomes of treatment, evaluation of economic parameters in the face of outcomes of clinical results, from different treatment options. Pharmaceutical companies implemented pharmacoeconomic principles for diversifying marketing approach and market access in pharmaceutical development. New healthcare systems demand increased costs for medical care, pharmaceutical products and medical devices. Process of medical costs for evaluation of costs evolved, indirect and hidden costs are part of sole process of evaluation. Health authorities from one side and pharmaceutical companies from other side developed unique methodologies for evaluation. With these implemented changes, traditional concept for evaluation of efficacy and safety of medical devices and pharmaceutical products was overbridged and pharmacoeconomics is base for research, development, registration, reimbursement, as well as dispensing and follow the life cycle of medicines. Results from antibiotic consumption analysis in Republic of Macedonia at 2016 showed that total antibiotic consumption and antibiotic consumption per DDD/1000 citizens is according to average EU trends, mostly similarly to the usage trends of low-income countries. But usage of new and innovative antibiotic is on very low level, which indicates the need of further implementing of pharmacoeconomic analysis and principles in decision making process, for improved health care for the patients. The ultimate goal of implementing the pharmacoeconomic system in each country is enhancing the benefit to the patient through improved resource allocation. Keywords: pharmacoeconomics, type of pharmacoeconomic analysis, antibiotic consumption, Republic of Macedonia
Highlights
Pharmacoeconomics research is the process of identifying, measuring, and comparing the costs, risks, and benefits of programs, services or therapies and determining which alternative produces the best health outcome for the resources invested (Drummond et al., 1989)
Usage of new and innovative antibiotic is on very low level, which indicates the need of further implementing of pharmacoeconomic analysis and principles in decision making process, for improved health care for the patients
In order to evaluate antibiotic consumption in Republic of Macedonia for 2016, we evaluate consumption according to the Annual Report for 2016 published by Health Insurance Fund (HIF) of Republic of Macedonia
Summary
Pharmacoeconomics research is the process of identifying, measuring, and comparing the costs, risks, and benefits of programs, services or therapies and determining which alternative produces the best health outcome for the resources invested (Drummond et al., 1989). Pharmacoeconomic analysis correlates the cost of providing a medical service, using pharmaceutical product or medical device, with outcomes realized by using that specific product or service. This information can assist to clinical decision makers and health care policy makers in choosing the most costeffective treatment options. The aim of pharmacoeconomic analysis is to improve individual and public health, by making decisions and determining the. Health insurance companies in developed countries use pharmacoeconomic analysis to evaluate variations in structure and volume of used medicines, with sole aim to improve and develop process of allocation of resources. Many issues regarding uncertainties which product should be used can be resolved with varieties of pharmacoeconomic analysis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
